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Chapter 1 
Introduction 
 
1.1  A Chemical Understanding of the Brain 
 The brain is the most complex organ in the human body.  On average, the adult 
human brain contains 10
11
 neurons, each of which makes 10
3
 to 10
4
 interactions with 
other neurons through junctions called synapses.  Communication from one neuron to 
another takes place through synaptic transmission.  Each synapse involves the 
communication of two neurons (Figure 1.1), the one producing the signal, called the pre-
synaptic neuron, and the one receiving it, called the post-synaptic neuron.  The pre-
synaptic neuron receives information from other neurons through its dendrites.  After 
processing this information, the neuron fires an electrical impulse, the action potential, 
which travels down the axon of the pre-synaptic neuron.  Upon reaching the axon 
terminus, the electrical impulse causes vesicles containing neurotransmitter to fuse to the 
cell membrane, thereby releasing neurotransmitter into the synaptic cleft, the small space 
between neurons.  This effectively turns the electrical signal, the action potential, into a 
chemical signal, the neurotransmitter.  Receptors within the cell membrane of the post-
synaptic neuron recognize and bind the neurotransmitters.  Activation of the 
neuroreceptors directly or indirectly leads to the flow of ions across the membrane of the 
post-synaptic cell, thereby converting the chemical signal back to an electrical one. 
Brain function is much more complex than simply understanding synaptic 
transmission.  Neuroreceptors are located in both the pre-synaptic and post-synaptic 
densities and recognize a variety of ligands. Their activation leads to a myriad of down-
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stream effects resulting from the flow of ions across the membrane.  Neurotransmitters 
are most often small organic molecules 
 
Figure 1.1  Synaptic Transmission.  A, The interaction of two neurons takes place between the axon 
terminus (pink) of the pre-synaptic cell and the dendrites (purple) of the post-synaptic cell.  The synapse is 
highlighted (red box).  B, A cartoon of synaptic transmission.  Neurotransmitter is depicted as blue dots. 
 
but can also be peptides or fatty acids.  The electrical signals that result from 
neuroreceptor activation can be either inhibitory or excitatory.  A given neuron receives 
multiple signals at different synapses, further complicating matters.  The interplay of 
various inputs at specific regions of the brain give rise to higher brain function, including 
learning and memory, addiction, and sensory input.  Given the complexity of the brain, 
how can we hope to use chemical-scale studies to elucidate brain function? 
 We focus our efforts on developing an in-depth understanding of a specific type 
of neuroreceptor – the Cys-loop ligand gated ion channels.  Neurotransmitter binding and 
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activation of the receptor are chemical-scale events that can be studied by site-specific 
incorporation of unnatural amino acids. 
1.2 Cys-loop ligand gated ion channels 
 The Cys-loop ligand gated ion channels constitute a superfamily of receptors that 
mediate rapid synaptic transmission in the mammalian central and peripheral nervous 
systems through the binding of a neurotransmitter agonist.  At rest, the receptor is in an 
unliganded, closed, non conducting state.  Upon binding of agonist, the receptor 
undergoes a conformational change to an open ion-conducting state, thereby allowing 
ions to cross the cell membrane.  The conformational change removes a hydrophobic 
barrier that prevents ion permeation, analogous to a gate swinging open; therefore the 
change from the closed state to the open state is often referred to as channel gating.   
 
Figure 1.2 General topology of Cys-loop receptors.  A, The nAChR, a prototypical Cys-loop receptor, has 
two 1 (blue), one 1 (green), one  (red), and one  or  (yellow) subunit.  B, Each subunit has a 
predominantly beta sheet, N-terminal extracellular domain and four membrane-spanning helices.  The 
ligand binding site and channel gate are highlighted as VDW residues.   
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 The superfamily includes the excitatory, cation conducting, nicotinic 
acetylcholine receptors (nAChR) and serotonin type 3A receptors (5HT3AR), as well as 
the inhibitory, anion conducting, -aminobutyric acid (GABA) type A and type C 
receptors (GABAAR and GABACR, respectively) and the glycine receptors (GlyR).  Each 
receptor is comprised of five homologous subunits arranged pseudosymmetrically around 
a central, ion-conducting pore (Figure 1.2).  The large N-terminal domain of each subunit 
has a predominantly beta sheet structure with short loops connecting the beta strands.  
The primary sequence leads directly from beta strand 10 to four membrane-spanning 
helices, termed M1-M4, followed by a short, extracellular, carboxy terminus.  The M2 
helix of each subunit lines the channel pore.  Neurotransmitter binding sites are located at 
select subunit interfaces in the extracellular domain, while the channel gate is located 
~60Å away in the transmembrane region. 
 These large, membrane-spanning proteins do not readily lend themselves to 
crystallization techniques. As such, there are no crystal structures of mammalian Cys-
loop neurotransmitter gated ion channels.  Instead, structural information about these 
receptors relies heavily on biochemical studies as well as X-ray crystallography data from 
the acetylcholine binding protein (AChBP) and cryo-EM images of the nAChRs found in 
the electroplaques of the Torpedo californica ray.  AChBP is a soluble pentameric protein 
isolated from snails which is highly homologous to the extracellular portion of Cys-loop 
neurotransmitter gated ion channels.   Unlike the Cys-loop receptors, the role of AChBP 
is to bind acetylcholine, not to open an ion pore.  Thus, while structural information from 
AChBP is useful in determining residues involved in neurotransmitter binding, the 
structure provides no information about the activation or gating pathway of the 
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mammalian ion channels.  Cryo-EM is an inherently lower resolution methodology than 
X-ray crystallography, thus the amino acid side chains cannot be resolved.  However, the 
cryo-EM image is the only structure of a full mammalian Cys-loop ligand gated ion 
channel, and has a higher sequence homology to nAChRs than AChBP.  As such, the 
cryo-EM structure (Protein Data Bank code 2BG9) can guide studies relating to the 
gating pathway of these receptors more readily than AChBP structures. 
1.3 Unnatural Amino Acid Methodology 
1.3.1 Advantage of Unnatural Amino Acids 
 To study neuroreceptors on the chemical-scale, we need a precise methodology 
that allows us to investigate these proteins as we would small organic molecules on a 
bench top.  The analogous experiments for neuroreceptors and their ligands are structure-
function studies. Manipulation of the neurotransmitter can be carried out synthetically 
and has been done so extensively by medicinal chemists and pharmacologists.  
Derivatizing and making analogues of the neurotransmitters provides information 
regarding the action of neurotransmitter on neurons, and can elucidate the 
neurotransmitter pharmacaphore, but does not provide data on the structural 
rearrangements within the neuroreceptor.  Conducting similar studies where the structural 
perturbations are restricted to the neuroreceptor allows the nature of the interactions with 
the receptor to be illuminated. 
 Cys-loop neurotransmitter-gated ion channels are multimeric membrane proteins 
of over two-thousand amino acids, and thus cannot be made synthetically.  Furthermore, 
accurate evaluation of receptor function requires the proteins to be membrane bound.  
Mutagenesis of the receptor and expression in a heterologous system provide a means to 
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both perturb protein structure and preserve an in vivo context for channel function.  
However, mutagenesis restricts the structural perturbations to those contained within the 
twenty naturally occurring amino acids (Figure 1.3).     
 
Figure 1.3 Side chains of the natural amino acids.  From left to right: top row: proline, glycine (shown as 
full amino acid), alanine, valine, isoleucine, leucine, methioninine, tyrosine.  Middle row: glutamate, 
aspartate, arginine, lysine, phenylalanine, tryptophan.  Bottom row: glutamine, asparagine, threonine, 
serine, cysteine, histidine 
 
 The twenty naturally occurring amino acids have limited chemical functionality in 
their side chains.  For example, there are no side chains with ketones, alkenes, or nitro 
groups.  Even within the chemical functionality provided by these twenty amino acids, 
the overall shape, size, and length of the side chain is predetermined for a given 
functionality.  For example, mutation from serine to cysteine replaces a hydroxyl group 
with a sulfhydryl group, yet there is no corresponding mutation for a threonine residue.  
Additionally, the interaction of two amino acids within the neuroreceptor may require 
augmenting side chain length or polarity or conversion of the amide peptide bond to an 
ester linkage. None of these objectives are accurately achieved using conventional 
mutagenesis.  Incorporation of unnatural amino acids, however, allows the introduction 
of novel side chains to precisely determine the role of a specific amino acid.   
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  While unnatural amino acids provide a virtually limitless pool of structural 
perturbations (Figure 1.4), how can we incorporate them into our proteins?  Synthetic 
incorporation is not feasible for large, transmembrane bound proteins such as Cys-loop 
neurotransmitter gated ion channels.  Instead we rely on the site-specific nonsense 
suppression methodology. 
 
Figure 1.4 A subset of unnatural amino acid side chains and alpha hydroxy acids incorporated via the 
nonsense suppression methodology
1
 
 
1.3.2 Nonsense Suppression Methodology 
 The ability to site-specifically incorporate unnatural amino acids into proteins was 
developed by Schultz and co-workers in 1989.
2-11
  To achieve incorporation at a specific 
site, a codon that is not recognized by any of the native tRNAs must be utilized, a tRNA 
molecule recognizing this codon must be made, and the unnatural amino acid must be 
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chemically attached to the tRNA molecule.  Only three codons, UAG, UAA, and UGA, 
do not code for one of the twenty naturally occurring amino acids.  These three codons 
are STOP codons and normally mark the termination of translation.  We incorporate a 
STOP codon at the site of interest and engineer a tRNA molecule with the appropriate 
anticodon.  Instead of terminating protein translation when the STOP codon is reached, 
the ribosome incorporates the unnatural amino acid at this site as it would incorporate any 
of the naturally occurring amino acids (Figure 1.5). 
 
Figure 1.5 Overview of unnatural amino acid incorporation using nonsense suppression 
 
 Nonsense suppression requires a combination of molecular biology and chemical 
synthesis.
9,12-15
  Most often, the amber codon, UAG, is used as the STOP codon because 
it was the first developed
8
 and the suppressor tRNA engineered to recognize this codon 
has been shown to be more efficient.
16,17
  The UAG mutation is first incorporated into the 
gene via quickchange PCR.  In vitro transcription is used to make mRNA based on the 
DNA template.  The suppressor tRNA without the last two nucleotides (C and A) of the 
acceptor stem are transcribed in vitro.  The last two ribonucleotides of all tRNA 
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molecules are CA.  Deoxy-CA (dCA) is chemically synthesized and the unnatural amino 
acid is attached chemically to give Uaa-dCA.  The unnatural amino acids are prepared by 
addition of a photo- (NVOC) or iodine- (4-PO) labile amino protecting group.  The 
carboxylic acid is activated as the cyanomethyl ester prior to acylation of the dCA 
molecule (Figure 1.6) to give Uaa-dCA.  Once acylated, the dCA is ligated to the 
truncated suppressor tRNA using T4 RNA ligase to yield the full length amino-acylated 
tRNA.  The amino group of the Uaa is left protected to stabilize the acylated tRNA. 
 
Figure 1.6 Standard preparation of unnatural amino acid (Uaa) coupled to deoxy-Cytosine, Adenine (dCA) 
 
Immediately prior to injection into Xenopus laevis oocytes (Figure 1.7), the amino 
group of the unnatural amino acid is deprotected, and tRNA-Uaa is mixed with mRNA.  
Each oocyte is injected with 50 nL of RNA mix and then allowed to incubate for twenty-
four to forty-eight hours.  During this time, the Cys-loop neurotransmitter gated ion 
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channels are transcribed, folded, processed, assembled, and transported to the cell 
surface.  Once an unnatural amino acid is incorporated into the nascent protein chain, the 
tRNA is released back into the cell.  However, there is not a way to put more Uaa on the 
tRNA molecule, thus the Uaa-tRNA is used as a stoichiometric reagent, thereby limiting 
the amount of protein made.  Fortunately, these ion channels can be evaluated by 
electrophysiology, a highly sensitive assay that detects currents through the whole cell.  
 
Figure 1.7 Implementation of nonsense suppression methodology using Xenopus laevis oocytes 
 
 
 Direct application of neurotransmitter to the oocytes results in neurotransmitter 
binding to the surface-expressed receptors followed by activation to the open state.  The 
flow of ions across the cell membrane produces a macroscopic whole cell current that can 
be measured (Figure 1.8) by the two-electrode voltage clamp method.  The amount of 
current is dependent on the number of surface expressed receptors, the proportion of the 
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receptors binding neurotransmitter, and the ability of the drug to activate the receptor.  
Applying increasing concentrations of agonist results in larger whole cell currents (Figure 
1.8B).  The relationship between the concentration of neurotransmitter, or drug, and the 
current size is the dose response relationship (Figure 1.8C).  The EC50, or effective 
concentration to induce the half-maximal response, is used as a metric of ion channel 
function.  A leftward shift in EC50 is termed gain of function because less 
neurotransmitter is required to achieve the same level of activation.  A rightward shift in 
EC50 is a loss of function mutation because more neurotransmitter is required to achieve 
the same level of activation.  The EC50 is an equilibrium measurement dependent on both 
neurotransmitter binding and the potency (ability to activate the neuroreceptor) of the 
neurotransmitter.  
 
Figure 1.8  Typical electrophysiology assay.  (A) Neurotransmitter, or agonist, (stars) binds to the 
neurotransmitter gated ion channels which leads to receptor gating and ion flow. (B) The current size 
increases as the concentration of agonist is increased until all receptors are saturated.  (C) The dose 
response relationship is determined and fit to the Hill equation (D) to give the EC50 and Hill coefficient (n). 
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1.4 Dissertation Work 
 This dissertation describes multiple studies that utilize conventional mutagenesis as 
well as unnatural amino acid incorporation combined with electrophysiology.  These 
studies focused on individual members of the Cys-loop ligand gated ion channel (LGIC) 
superfamily, specifically the muscle-type nAChR, the 12 and 122 GABAAR, and the 
1GlyR.   
 Chapters 2 through 4 describe research investigating the role of loop 2 residues in 
the 1 subunit of nAChRs during channel activation.  The highly charged nature of the 
loop is investigated through conventional mutagenesis in Chapter 2.
18
  Mutation of loop 2 
residues to histidine followed by pH experiments to change the protonation state of the 
loop are the subject of Chapter 3.  In Chapter 4, site-specific incorporation of unnatural 
amino acids is used to evaluate a proposed interaction
19-23
 between a loop 2 residue and 
the transmembrane domain of the receptors.  Due to the precision of the nonsense 
suppression methodology, this study
24
 is more conclusive than any previous study
25,26
 
investigating this interaction.  
 In Chapter 5, our focus shifts to the binding site of two inhibitory members of the 
Cys-loop family; the 12 GABAAR, and 1GlyR.  Herein we identify the location and 
strength of a cation-  interaction formed between the cognate neurotransmitter and 
neuroreceptor by introduction of fluorinated phenylalanine residues. 
 Finally, Chapters 6 and 7 discuss our efforts to identify the role of an unstructured 
linker in the 1 subunit of GABAARs in channel activation and benzodizapine 
potentiation.  We investigate both side chain and backbone mutations which affect the 
gating pathway of these receptors. 
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